Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Company Drug

Staidson Launches Phase Ia Trial for STSP-0902 Injection in Oligoasthenozoospermia

Fineline Cube Aug 16, 2024

Staidson (Beijing) Pharmaceutical Co., Ltd. (SHE: 300204) has announced that it has received approval from...

Company Drug

Jiangsu Hengrui Secures NMPA Approval for Clinical Trials of SHR-2106 in Primary Sjögren’s Syndrome

Fineline Cube Aug 16, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received clinical trial...

Company Medical Device

Lepu Scientech Secures NMPA Approval for MemoSORB Biodegradable Atrial Septal Defect Occluder

Fineline Cube Aug 16, 2024

Lepu Scientech Medical Technology (Shanghai) Co., Ltd. (HKG: 2291) has announced that it has received...

Company Medical Device

Sino Medical Secures Moroccan Approvals for NC Rockstar Catheter and HT Supreme Stent System

Fineline Cube Aug 16, 2024

Sino Medical Sciences Technology Inc. (SHA: 688108), a prominent player in China’s medical device sector,...

Company Drug

Vimgreen Pharma Launches Phase II Trial for A2AR Antagonist VG081821AC in Parkinson’s Disease

Fineline Cube Aug 16, 2024

Zhejiang-based Vimgreen Pharma has announced the launch of a Phase II clinical trial for its...

Company Drug

Gilead Secures FDA Accelerated Approval for Livdelzi in Liver Disease Treatment

Fineline Cube Aug 15, 2024

Gilead Sciences Inc. (NASDAQ: GILD) has received accelerated approval from the U.S. FDA for its...

Company Drug

Astellas Pharma Secures UK Approval for First-in-Class Gastric Cancer Therapy Vyloy

Fineline Cube Aug 15, 2024

Astellas Pharma (TYO: 4503), a leading Japanese pharmaceutical company, has secured market approval in the...

Company

GSK’s Ma Zheng to Depart as Head of Communication and Government Affairs in China

Fineline Cube Aug 15, 2024

Ma Zheng, the head of communication and government affairs for GSK plc (NYSE: GSK) in...

Company Deals Medical Device

Shanghai Sanyou Medical to Acquire Full Control of SMTP Technology for RMB 415.7 Million

Fineline Cube Aug 15, 2024

Shanghai Sanyou Medical Co., Ltd. (SHA: 688085), based in China, is set to acquire the...

Company Deals Drug

Shandong Buchang Pharmaceuticals Partners with Lancet for BC001 Licensing in Eurasia

Fineline Cube Aug 15, 2024

Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858), based in China, has announced plans to enter...

Company Drug

Biogen and Eisai Secure UAE Approval for Alzheimer’s Therapy Leqembi

Fineline Cube Aug 15, 2024

Biogen Inc. (NASDAQ: BIIB), based in the U.S., and Japan’s Eisai Co., Ltd. have announced...

Policy / Regulatory

Shaanxi Leads New Provincial Alliance for Volume-Based Procurement of Medical Products

Fineline Cube Aug 15, 2024

The Shaanxi Public Resources Trading Center has announced the formation of a provincial alliance for...

Company Drug

CStone to Manufacture Gavreto Locally Following NMPA Approval, Expanding Market Presence

Fineline Cube Aug 15, 2024

CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has received approval from the National Medical...

Company Medical Device

China’s Sansure Biotech Launches Approved Kit for Alzheimer’s and Cardiovascular Risk Assessment

Fineline Cube Aug 15, 2024

Sansure Biotech Inc. (SHA: 688289), a China-based leader in molecular diagnostics, has secured marketing approval...

Company Drug

Qilu Pharmaceutical Gains Approval for Generic Dasatinib, Expanding CML Treatment Options in China

Fineline Cube Aug 14, 2024

Qilu Pharmaceutical, based in China, has received marketing approval for its generic version of Bristol-Myers...

Company

Eli Lilly Unveils $700 Million R&D Center in Boston to Boost Genetic Medicine Efforts

Fineline Cube Aug 14, 2024

Eli Lilly & Co. (NYSE: LLY) has inaugurated its new R&D center in Boston’s Seaport...

Company Drug

Ascentage Pharma Secures NMPA Approval for Phase III Trial of Lisaftoclax in MDS

Fineline Cube Aug 14, 2024

Ascentage Pharma (HKG: 6855), based in China, has received approval from the National Medical Products...

Company Drug

Enhertu Gains Conditional Approval in China for Advanced HER2-Positive Gastric Cancer

Fineline Cube Aug 14, 2024

Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody-drug conjugate co-developed by AstraZeneca (NASDAQ: AZN, LON: AZN) and...

Company Deals R&D

New Agreement Enhances Myopia Solutions: Hong Kong Polytechnic and Zeiss Collaborate

Fineline Cube Aug 14, 2024

The School of Optometry at Hong Kong Polytechnic University has announced a new cooperation agreement...

Company Medical Device

Lepu Medical’s PeakHeat Vascular Sheath Gains Regulatory Green Light for Market Launch

Fineline Cube Aug 14, 2024

Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease solutions...

Posts pagination

1 … 337 338 339 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.